Established in 1989 as a spin out from Queen Mary University, London, hVIVO part of Open Orphan plc is a trusted partner and industry-leading clinical development services, pioneering in human challenge studies. hVIVO’s clinical trial platform can help accelerate drug and vaccine development in respiratory and infectious disease.
hVIVO’s, formally known as Retroscreen, has an extensive history in conducting & running clinical trials, which has aided to their strong position as world leaders in clinical trial research and execution.
In 2011 hVIVO opened their laboratory, screening and 24-bedroom quarantine facilities to Queen Mary BioEnterprises in Whitechapel, London. In 2021, the quarantine facilities expanded to a 19-bedroom hotel, offering volunteers a state-of-the-art clinical trial experience.
Our services are provided and tailored for both pharmaceutical and biotech companies, utilising a range of different clinical trial and laboratory methodologies across various viral challenges. Our extensive experience, collected over 50 years of conducting challenge studies, ensures effective study design and excellent service for customers.
The Company has a leading portfolio of 9 challenge study models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough, 1 COPD, 1 COVID-19, 1 Malaria challenge models.
In addition, hVIVO offers laboratory services through their hLab unit, based in Whitechapel, London. Our hLab’s are a highly specialised virology and immunology laboratory offering a suite of services to support pre-clinical and clinical respiratory drug and vaccine discovery & development.
Reliable laboratory analysis underpinned by scientific expertise is essential when processing and analysing clinical samples. Robust quality processes support our team of scientists in the delivery of submission ready data.
Challenge Study Models
Quarantine Clinic Beds
Years of Combined Service
Number of Studies Completed in the Past 5 Years
One of hVIVO’s distinct advantages in their clinical trial research is the access to healthy volunteers to take part in clinical trial research, through their volunteer recruitment arm, FluCamp.
FluCamp welcome volunteers take part in hVIVO clinical trials under expertly supervised conditions, to further medical research and help take the understanding of respiratory, viral, and other infectious diseases to a new level.
In January 2020, hVIVO merged with Open Orphan plc a rapidly growing niche CRO pharmaceutical services company which comprises of two commercial specialist CRO services businesses hVIVO and Venn Life Sciences. Venn Life Sciences, as an integrated drug development consultancy, which offers CMC (chemistry, manufacturing and controls), preclinical, Phase I & II clinical trials design and execution.
The merger with hVIVO created a European full pharma services company broadening the Company’s customer base and with complementary specialist CRO services, widened the range of the Company’s service offerings.
Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials.
Venn Life Sciences is an Integrated Drug Development partner offering a unique combination of drug development consultancy, clinical trial design and execution.
FluCamp welcome volunteers to take part in our clinical trials under expertly supervised conditions.
hVIVO formed a Joint Venture in 2016 with PepTcell Limited called Imutex Limited, with hVIVO owning 49%, to develop vaccines against influenza (flu) and mosquito borne diseases such as Zika, Malaria and other flaviviruses.
hVIVO’s has an extensive history, that dates back to the UK Common Cold Unit in Salisbury which ran human challenge studies from 1946 until 1989. The facility was a former military hospital that was donated by Harvard University and began human challenge studies to try to find a cure for influenza.
The company founders, Professor John Oxford and Dr Robert Lambkin Williams, worked at the Common Cold Unit alongside Dr David Tyrell, and after it closed, went on to setup Retroscreen Virology Limited out of Queens Mary University in 1989.
Retroscreen, renamed hVIVO in 2015 as part of its IPO on the London Stock Exchange, continues its challenge study work right up to the present day. hVIVO is now the world leader in providing human challenge studies to test infectious and respiratory product and we have the widest portfolio of challenge models available in influenza, respiratory syncytial virus (RSV), human rhinovirus (HRV), asthma, COPD, cough, malaria, and most recently COVID-19. A number of the same techniques used at the Common Cold Unit are still used by hVIVO today, though needless to say they have modernised.
At hVIVO, we understand the vital role we play in making infectious and respiratory disease products available to patients faster than otherwise possible, using human challenge trials. With origins dating back to 1947, hVIVO has a long history of scientific research and discovery which has helped to advance global health.
Our most valuable asset is our team, and we strive to promote a diversified and welcoming environment which allows our team to thrive. We are committed to ethical and compliant business practices, from the execution of our clinical trials to our interactions with our volunteers, clients, sponsors, vendors, and investors.
We understand our responsibility to reduce our impact on the environment whenever possible, we strive to minimise our carbon footprint through energy efficiencies, local and sustainable suppliers, and waste reduction.